These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 39197909)

  • 1. Potential of Nutritional Markers as Predictors After Immunotherapy in Advanced Head and Neck Squamous Cell Carcinoma.
    Matsumura S; Kaira K; Kuba K; Inoue H; Hamada M; Yamazaki T; Nakahira M; Ebihara Y
    Anticancer Res; 2024 Sep; 44(9):4049-4056. PubMed ID: 39197909
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hypoalbuminemia and hypercalcemia are independently associated with poor treatment outcomes of anti-PD-1 immune checkpoint inhibitors in patients with recurrent or metastatic head and neck squamous cell carcinoma.
    Chiu TJ; Huang TL; Chien CY; Huang WT; Li SH
    World J Surg Oncol; 2024 Sep; 22(1):242. PubMed ID: 39256833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes and Biomarkers of Immune Checkpoint Inhibitor Therapy in Patients with Refractory Head and Neck Squamous Cell Carcinoma: KCSG HN18-12.
    Lee YG; Chang H; Keam B; Chun SH; Park J; Park KU; Shin SH; An HJ; Lee KE; Lee KW; Kim HR; Kim SB; Ahn MJ; Hwang IG
    Cancer Res Treat; 2021 Jul; 53(3):671-677. PubMed ID: 33285051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The predictive value of a preoperative systemic immune-inflammation index and prognostic nutritional index in patients with esophageal squamous cell carcinoma.
    Zhang H; Shang X; Ren P; Gong L; Ahmed A; Ma Z; Ma R; Wu X; Xiao X; Jiang H; Tang P; Yu Z
    J Cell Physiol; 2019 Feb; 234(2):1794-1802. PubMed ID: 30070689
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A systematic review and meta-analysis of prognostic indicators in patients with head and neck malignancy treated with immune checkpoint inhibitors.
    Kang D; Liu S; Yuan X; Liu S; Zhang Z; He Z; Yin X; Mao H
    J Cancer Res Clin Oncol; 2023 Dec; 149(20):18215-18240. PubMed ID: 38078963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutrophil-to-lymphocyte ratio associates with nutritional parameters, intratumoral immune profiles, and clinical outcomes of pembrolizumab in head and neck squamous cell carcinoma.
    Morimoto H; Tsujikawa T; Miyagawa-Hayashino A; Kimura A; Saburi S; Murakami N; Kitamoto K; Mukudai S; Nagao H; Saya S; Ogi H; Konishi E; Itoh K; Hirano S
    Head Neck; 2024 Aug; 46(8):1956-1964. PubMed ID: 38344945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relation of baseline neutrophil-to-lymphocyte ratio to survival and toxicity in head and neck cancer patients treated with (chemo-) radiation.
    Bojaxhiu B; Templeton AJ; Elicin O; Shelan M; Zaugg K; Walser M; Giger R; Aebersold DM; Dal Pra A
    Radiat Oncol; 2018 Nov; 13(1):216. PubMed ID: 30400969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Utility of prognostic nutritional index and systemic immune-inflammation index in oral cancer treatment.
    Kubota K; Ito R; Narita N; Tanaka Y; Furudate K; Akiyama N; Chih CH; Komatsu S; Kobayashi W
    BMC Cancer; 2022 Apr; 22(1):368. PubMed ID: 35392843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Systemic immune response in squamous cell carcinoma of the head and neck: a comparative concordance index analysis.
    Tham T; Wotman M; Chung C; Ahn S; Dupuis H; Gliagias V; Movsesova T; Kraus D; Costantino P
    Eur Arch Otorhinolaryngol; 2019 Oct; 276(10):2913-2922. PubMed ID: 31312922
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell lung cancer treated with nivolumab.
    Liu J; Li S; Zhang S; Liu Y; Ma L; Zhu J; Xin Y; Wang Y; Yang C; Cheng Y
    J Clin Lab Anal; 2019 Oct; 33(8):e22964. PubMed ID: 31282096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nutritional status associates with immunotherapy clinical outcomes in recurrent or metastatic head and neck squamous cell carcinoma patients.
    Hernando-Calvo A; Mirallas O; Marmolejo D; Saavedra O; Vieito M; Assaf Pastrana JD; Aguilar S; Bescós C; Lorente J; Giralt J; Benavente S; Temprana-Salvador J; Alberola M; Dienstmann R; Garralda E; Felip E; Villacampa G; Brana I
    Oral Oncol; 2023 May; 140():106364. PubMed ID: 36989964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.
    Xu X; Li R; Zhang L; Zhu G; Ren D; Wu L; Gong X
    Diagn Pathol; 2021 Nov; 16(1):110. PubMed ID: 34823553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive value of immunotherapy-induced inflammation indexes: dynamic changes in patients with nasopharyngeal carcinoma receiving immune checkpoint inhibitors.
    Cao J; Chen Q; Bai X; Liu L; Ma W; Lin C; Lu F; Zhou T; Zhan J; Huang Y; Yang Y; Luo F; Zhao H
    Ann Med; 2023; 55(2):2280002. PubMed ID: 38065623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic value of inflammatory markers NLR, PLR, and LMR in gastric cancer patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.
    Tan S; Zheng Q; Zhang W; Zhou M; Xia C; Feng W
    Front Immunol; 2024; 15():1408700. PubMed ID: 39050856
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Relationship Between Preoperative Systemic Immune Inflammation Index and Prognostic Nutritional Index and the Prognosis of Patients With Alveolar Hydatid Disease.
    Ren B; Chen X; Lei P; Hou L; Wang H; Zhou Y; Ren L; Fan H; Wang Z; Yuan J
    Front Immunol; 2021; 12():691364. PubMed ID: 34248983
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Hematological Markers in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Treated With Pembrolizumab.
    Hagiwara K; Matsuki T; Okada T; Fushimi C; Kondo T; Takahashi H; Okamoto I; Tokashiki K; Hanyu K; Kishida T; Ito T; Yamashita G; Tsukahara K; Masubuchi T; Tada Y; Momiyama K; Yaguchi R; Oridate N; Omura GO; Yamashita T
    Anticancer Res; 2024 Sep; 44(9):4057-4072. PubMed ID: 39197913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Utility of Inflammatory and Nutritious Index as Therapeutic Prediction of Nivolumab plus Ipilimumab in Advanced Non-Small Cell Lung Cancer.
    Yamaguchi O; Kaira K; Imai H; Mouri A; Shiono A; Miura Y; Hashimoto K; Kobayashi K; Kagamu H
    Oncology; 2024; 102(3):271-282. PubMed ID: 37725914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On-treatment immune prognostic score for patients with relapsed and/or metastatic head and neck squamous cell carcinoma treated with immunotherapy.
    Nenclares P; Gunn L; Soliman H; Bover M; Trinh A; Leslie I; Wong KH; Melcher A; Newbold K; Nutting CM; Ap Dafydd D; Bhide SA; Harrington K
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103355
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA methylation profiles differ in responders versus non-responders to anti-PD-1 immune checkpoint inhibitors in patients with advanced and metastatic head and neck squamous cell carcinoma.
    Starzer AM; Heller G; Tomasich E; Melchardt T; Feldmann K; Hatziioannou T; Traint S; Minichsdorfer C; Schwarz-Nemec U; Nackenhorst M; Müllauer L; Preusser M; Berghoff AS; Fuereder T
    J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35338086
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of nutritional indices in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors.
    Miyamoto N; Takenaka Y; Sudo T; Eguchi H; Tanaka H; Fukusumi T; Takemoto N; Suzuki M; Inohara H
    Acta Otolaryngol; 2023 Oct; 143(10):925-930. PubMed ID: 38059478
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.